Close

Pluristem Therapeutics (PSTI) Secures Orphan Drug Designation for Its PLX-R18 Cell Therapy

October 19, 2017 7:34 AM EDT Send to a Friend
Pluristem Therapeutics Inc. (NASDAQ: PSTI) announced today that the U.S. Food and Drug Administration (FDA) has granted the company an ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login